CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Trametinib

曲美替尼 杂质对照品Trametinib Impurities

23 个杂质条目23 impurity entries

本页汇总 曲美替尼 的 23 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 23 impurity reference standards of Trametinib. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 曲美替尼(Trametinib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesNew stability indicating RP-HPLC methods for the determination of related substances and assay of trametinib acetic acid: a mass balance approach
    Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024 · Himabindu G et al.  ·  PMID 39080194  ·  DOI
  2. 杂质研究Impurity studiesCorrection: New stability indicating RP-HPLC methods for the determination of related substances and assay of trametinib acetic acid: a mass balance approach
    Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024 · Himabindu G et al.  ·  PMID 39164468  ·  DOI
  3. 杂质研究Impurity studiesIdentification and characterization of trametinib degradation product employing Orbitrap LC-HRMS, and development of a robust, eco-friendly stability indicating method of analysis
    Journal of pharmaceutical and biomedical analysis · 2026 · Jawarkar SG et al.  ·  PMID 41564726  ·  DOI
  4. 分析方法Analytical MethodsSimultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry
    Journal of pharmaceutical and biomedical analysis · 2021 · Balakirouchenane D et al.  ·  PMID 33166838  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of the PET Tracer (124)I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020 · Pratt EC et al.  ·  PMID 32444378  ·  DOI

曲美替尼 —— 原料药与杂质对照品Trametinib — drug substance & impurities

共 24 个条目(含原料药本体)24 items incl. the drug substance
Trametinib structure
原料药 APIAPI
曲美替尼Trametinib
Trametinib
CAS No.871700-17-3
Chemical FormulaC26H23FIN5O4
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib DMSO structure
—
曲美替尼 二甲亚砜Trametinib DMSO
Trametinib DMSO
CAS No.1187431-43-1
Chemical FormulaC26H23FIN5O4·C2H6OS
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 1 structure
1
曲美替尼杂质1Trametinib Impurity 1
Trametinib Impurity 1
CAS No.1383430-03-2
Chemical FormulaC26H23FIN5O5
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 3 structure
3
曲美替尼杂质3Trametinib Impurity 3
Trametinib Impurity 3
CAS No.871700-65-1
Chemical FormulaC26H24FN5O4
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib impurity 04 structure
04
曲美替尼杂质04Trametinib impurity 04
Trametinib impurity 04
CAS No.871700-25-3
Chemical FormulaC26H23FIN5O4
Purity>95%现货In stock
10mg25mg50mg100mg
Trametinib Impurity 4 structure
4
曲美替尼杂质4Trametinib Impurity 4
Trametinib Impurity 4
CAS No.3018911-27-5
Chemical FormulaC17H17FIN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 5 structure
5
曲美替尼杂质5Trametinib Impurity 5
Trametinib Impurity 5
CAS No.871700-24-2
Chemical FormulaC18H15FIN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 6 structure
6
曲美替尼杂质6Trametinib Impurity 6
Trametinib Impurity 6
CAS No.871701-87-0
Chemical FormulaC24H21FIN5O3
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 7 structure
7
曲美替尼杂质7Trametinib Impurity 7
Trametinib Impurity 7
CAS No.871700-28-6
Chemical FormulaC13H11FIN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 8 structure
8
曲美替尼杂质8Trametinib Impurity 8
Trametinib Impurity 8
CAS No.871700-22-0
Chemical FormulaC14H13FIN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity N9 structure
N9
曲美替尼杂质N9Trametinib Impurity N9
Trametinib Impurity N9
CAS No.871700-41-3
Chemical FormulaC12H11FIN3O2
Purity>95%现货In stock
10mg25mg50mg100mg
Trametinib Impurity 10 structure
10
曲美替尼杂质10Trametinib Impurity 10
Trametinib Impurity 10
CAS No.871700-18-4
Chemical FormulaC10H10FIN2O
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity N10 structure
N10
曲美替尼杂质N10Trametinib Impurity N10
Trametinib Impurity N10
CAS No.1383430-04-3
Chemical FormulaC26H23FIN5O6
Purity>95%现货In stock
10mg25mg50mg100mg
Trametinib Impurity N11 structure
N11
曲美替尼杂质N11Trametinib Impurity N11
Trametinib Impurity N11
CAS No.871701-23-4
Chemical FormulaC26H23FIN5O4
Purity>95%现货In stock
10mg25mg50mg100mg
Trametinib Impurity 19 structure
19
曲美替尼杂质19Trametinib Impurity 19
Trametinib Impurity 19
CAS No.29632-74-4
Chemical FormulaC6H5FIN
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 20 structure
20
曲美替尼杂质20Trametinib Impurity 20
Trametinib Impurity 20
CAS No.871700-26-4
Chemical FormulaC13H11FIN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 21 structure
21
曲美替尼杂质21Trametinib Impurity 21
Trametinib Impurity 21
CAS No.102-28-3
Chemical FormulaC8H10N2O
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 22 structure
22
曲美替尼杂质22Trametinib Impurity 22
Trametinib Impurity 22
CAS No.1044058-33-4
Chemical FormulaC28H25FIN5O4
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 28 structure
28
曲美替尼杂质28Trametinib Impurity 28
Trametinib Impurity 28
CAS No.122-28-1
Chemical FormulaC8H8N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 30 structure
30
曲美替尼杂质30Trametinib Impurity 30
Trametinib Impurity 30
CAS No.34801-09-7
Chemical FormulaC8H10N2O
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 31 structure
31
曲美替尼杂质31Trametinib Impurity 31
Trametinib Impurity 31
CAS No.95-86-3
Chemical FormulaC6H8N2O
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 32 structure
32
曲美替尼杂质32Trametinib Impurity 32
Trametinib Impurity 32
CAS No.82099-55-6
Chemical FormulaC8H10N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 33 structure
33
曲美替尼杂质33Trametinib Impurity 33
Trametinib Impurity 33
CAS No.871700-30-0
Chemical FormulaC16H16FIN4O2
Purity>95%询价On request
10mg25mg50mg100mg
Trametinib Impurity 35 structure
35
曲美替尼杂质35Trametinib Impurity 35
Trametinib Impurity 35
CAS No.150-69-6
Chemical FormulaC9H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

曲美替尼 —— 研究文献与合成路线Trametinib — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 曲美替尼 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Trametinib. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. New stability indicating RP-HPLC methods for the determination of related substances and assay of trametinib acetic acid: a mass balance approach
    Himabindu G, Reddy YS, Prasad AVSS, et al. · Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024 · 被引 2cited 2
  2. Identification and characterization of trametinib degradation product employing Orbitrap LC-HRMS, and development of a robust, eco-friendly stability indicating method of analysis
    Jawarkar SG, Amliyar G, Khan N, et al. · Journal of pharmaceutical and biomedical analysis · 2026 · 被引 1cited 1
  3. Correction: New stability indicating RP-HPLC methods for the determination of related substances and assay of trametinib acetic acid: a mass balance approach
    Himabindu G, Reddy YS, Prasad AVSS, et al. · Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024

合成路线文献Synthetic-route papers

  1. Synthesis of the PET Tracer 124I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring
    Pratt EC, Isaac E, Stater EP, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

曲美替尼 杂质谱研究要点Trametinib — impurity profiling notes

下面这些是拿到 曲美替尼 的 24 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 24 impurity entries for Trametinib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances